人民财讯1月13日电，漱玉平民（301017）1月13日公告，持股6.67%的股东阿里健康科技(中国)有限公 司(简称"阿里健康")计划15个交易日后的3个月内，以集中竞价或大宗交易方式共计减持公司股份不超 过810.72万股，占公司总股本的2%。 ...

来源：智通财经 1月13日，港股开盘，恒生指数涨1.32%，恒生科技指数涨1.93%。科网股全线走强，阿里巴巴、阿里健 康涨近5%，百度集团涨近2%。 ...

智通财经APP讯，漱玉平民(301017.SZ)发布公告，持股5%以上股东阿里健康科技(中国)有限公司(以下 简称"阿里健康")计划在本公告发布之日起15个交易日后的3个月内(即2026年2月4日至2026年4月30日)， 以集中竞价和/或大宗交易方式共计减持公司股份不超过810.72万股，占公司总股本的2%。 ...

每经AI快讯，漱玉平民1月13日晚间发布公告称，漱玉平民大药房连锁股份有限公司持股5%以上股东阿 里健康科技（中国）有限公司（简称"阿里健康"）持有公司股份约2704万股（占公司总股本比例为 6.67%），计划在本公告发布之日起15个交易日后的3个月内，以集中竞价和/或大宗交易方式共计减持 公司股份不超过约811万股，占公司总股本的2%。 （记者 王晓波） 每经头条（nbdtoutiao）——"春节也要加班，抢在4月1日前交货"！有光伏企业在抢出口，也有企业很 纠结：白银等原材料成本激增，决策困难 ...

漱玉平民（301017）(301017.SZ)发布公告，持股5%以上股东阿里健康科技(中国)有限公司(以下简称"阿 里健康")计划在本公告发布之日起15个交易日后的3个月内(即2026年2月4日至2026年4月30日)，以集中 竞价和/或大宗交易方式共计减持公司股份不超过810.72万股，占公司总股本的2%。 ...

漱玉平民公告，持股5%以上股东阿里健康持有公司2703.91万股，占6.67%，计划自本公告披露15个交 易日后的2026年2月4日至2026年4月30日，通过集中竞价和/或大宗交易合计减持不超810.72万股，占公 司总股本2%。其中集中竞价不超405.36万股，占1%，大宗交易不超405.36万股，占1%；减持原因为自 身资金需求，股份来源为首次公开发行前取得的股份。 ...

Core Viewpoint - The news highlights the strong performance of WuXi AppTec, with significant revenue and profit growth projections for 2025, driven by its integrated CRDMO business model and increasing demand for its services [3][4]. Group 1: Company Performance - WuXi AppTec expects to achieve approximately 454.56 billion yuan in revenue for 2025, representing a year-on-year growth of about 15.84%, with a 21.4% increase in revenue from continuing operations [3]. - The adjusted net profit attributable to shareholders is projected to be around 149.57 billion yuan, reflecting a year-on-year increase of approximately 41.33% [3]. - The company has revised its revenue guidance upwards, with total revenue expectations adjusted from 425-435 billion yuan to 435-440 billion yuan for 2025 [3]. Group 2: Market Trends - The Hang Seng Biotechnology ETF (513280) saw a 1.57% increase, with trading volume exceeding 1.4 billion yuan, indicating a significant uptick in market interest [1]. - WuXi AppTec's stock rose over 8%, outperforming many peers in the biotechnology sector, which also saw positive movements [4]. Group 3: Industry Insights - The AI healthcare application sector is rapidly advancing, with significant policy support and market demand driving commercialization [6]. - AI in drug development is expected to enhance early-stage research efficiency, significantly reducing the time required for drug candidate identification [6][7]. - The integration of AI in healthcare is becoming increasingly prevalent, with tools like ChatGPT Health facilitating better health information management for users [8][9].

科网股表现分化，阿里巴巴、哔哩哔哩涨逾3%，阿里健康、零跑汽车等走高；商汤跌近5%，美的集 团、快手、华虹半导体均跌超2%。 编辑 ｜ 钉钉 1月13日，香港恒生指数收涨0.9%，恒生科技指数涨0.11%。 | 名称 | 现价 | 淵跌幅 ▼ | 淵跌 | | --- | --- | --- | --- | | 瑞科生物-B | 5.720 c | 37.50% | 1.560 | | 精优药业 | 0.099 c | 11.24% | 0.010 | | 直明最科-B | 6.730 c | 9.61% | 0.590 | | 药明康德 | 120,000 c | 8.30% | 9.200 | | 三济药业-B | 86.200 c | 8.29% | 6.600 | | 百興惠图-B | 42 760 c | 8.25% | 3.260 | | 泰格医药 | 53.500 c | 8.17% | 4.040 | | 荣昌生物 | 100.100 c | 7.87% | 7.300 | | 复宏汉霖 | 68.750 c | 6.42% | 4.150 | | 药明目信-B | 2.950 c | 6.1 ...

Core Insights - The article highlights a significant milestone in the treatment of infantile hemangiomas with the launch of a new drug, Malate Timolol Gel (brand name: Beimeijing®), developed by Beijing Melson Pharmaceutical Technology Co., Ltd. after 12 years of research [1] - Beimeijing® is the first and only topical gel approved for the treatment of "proliferative superficial infantile hemangiomas," marking a key advancement for China in this medical field [1] - The drug has received authoritative certification from the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original research drugs in the international market [1] Industry Context - Infantile hemangiomas are the most common benign tumors in infants in China, with a global incidence rate estimated between 5% and 12%, and superficial types accounting for nearly 70% [2] - The critical intervention period for effective treatment is within the first 1-6 months after birth, known as the "golden window," where timely treatment can prevent long-term skin issues [2] - Traditional treatment methods have faced limitations in safety, convenience, and accessibility, highlighting the need for specialized topical medications [2] Product Development - The development of Beimeijing® was based on core patents from the team of Professor Zheng Jiawei at Shanghai Jiao Tong University School of Medicine, involving a comprehensive process from molecular design to clinical validation [2] - The gel formulation allows for localized application, minimizing systemic exposure risks and enhancing safety for infants, making it a more convenient and non-invasive option compared to oral medications or surgical treatments [2] Clinical Efficacy - Phase III clinical trial data supports the advantages of Beimeijing®, showing a clinical cure rate of 60.7% and an overall efficacy rate of 89.4% among 121 infants aged 1-6 months, with good safety profiles [3] - The collaboration with Ali Health aims to create a comprehensive service ecosystem centered around the needs of children, ensuring that the standardized treatment approach is effectively communicated to families [3]

Group 1 - The core viewpoint of the article highlights the launch of a groundbreaking treatment for infantile hemangiomas in China, specifically the gel formulation of Timolol Maleate (brand name: Beimeijing®), which is the first and only approved topical gel for treating "proliferative superficial infantile hemangiomas" globally [1][2] - Beimeijing® was developed by Beijing Melson Pharmaceutical Technology Co., Ltd. over a span of twelve years, marking a significant advancement in the treatment of this condition, transitioning China from a follower to a leader in this medical field [1][2] - The product was officially launched on Alibaba Health, allowing parents to access the treatment through an online consultation, thus enhancing the accessibility and convenience of care for families [1][3] Group 2 - The drug received approval from the National Medical Products Administration (NMPA) on September 30, 2025, and has been recognized by the national drug pricing management system, establishing a traceable and referenceable price benchmark for Chinese original drugs in the international market [1][2] - The clinical consensus emphasizes the importance of intervention during the "golden window period" of 1-6 months after birth, as untreated hemangiomas can lead to permanent skin issues, highlighting the need for effective treatment options [2] - The gel formulation allows for localized application, significantly reducing systemic exposure risks and enhancing safety for infants, compared to traditional treatments such as oral medications or surgical interventions [2][3] Group 3 - Phase III clinical trial data supports the efficacy and safety of Beimeijing®, showing a clinical cure rate of 60.7% and an overall effective rate of 89.4% among 121 infants aged 1-6 months [3] - Alibaba Health aims to create a comprehensive service ecosystem centered around the child, facilitating the delivery of standardized treatment solutions and long-term management for families in need [3]